These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

486 related articles for article (PubMed ID: 33546983)

  • 21. Gut Microbiota and Renal Injury.
    Zhang L; Zhang W; Nie J
    Adv Exp Med Biol; 2020; 1238():93-106. PubMed ID: 32323182
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Modulation of the Gut Microbiota by Resistant Starch as a Treatment of Chronic Kidney Diseases: Evidence of Efficacy and Mechanistic Insights.
    Snelson M; Kellow NJ; Coughlan MT
    Adv Nutr; 2019 Mar; 10(2):303-320. PubMed ID: 30668615
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Microbiota metabolites: Pivotal players of cardiovascular damage in chronic kidney disease.
    Cosola C; Rocchetti MT; Cupisti A; Gesualdo L
    Pharmacol Res; 2018 Apr; 130():132-142. PubMed ID: 29518493
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Gut microbiota profiling reflects the renal dysfunction and psychological distress in patients with diabetic kidney disease.
    Li Q; Xie S; Liu Y; Yue W; Wang L; Liang Y; Chen Y; Yuan H; Yu J
    Front Endocrinol (Lausanne); 2024; 15():1410295. PubMed ID: 39076512
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The gut microbiome tango in the progression of chronic kidney disease and potential therapeutic strategies.
    Tang Z; Yu S; Pan Y
    J Transl Med; 2023 Oct; 21(1):689. PubMed ID: 37789439
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The Intestinal Microbiota Composition in Early and Late Stages of Diabetic Kidney Disease.
    Zhang L; Lu QY; Wu H; Cheng YL; Kang J; Xu ZG
    Microbiol Spectr; 2023 Aug; 11(4):e0038223. PubMed ID: 37341590
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Gut microbiota and inflammation in chronic kidney disease and their roles in the development of cardiovascular disease.
    Onal EM; Afsar B; Covic A; Vaziri ND; Kanbay M
    Hypertens Res; 2019 Feb; 42(2):123-140. PubMed ID: 30504819
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Homeostasis in the Gut Microbiota in Chronic Kidney Disease.
    Bhargava S; Merckelbach E; Noels H; Vohra A; Jankowski J
    Toxins (Basel); 2022 Sep; 14(10):. PubMed ID: 36287917
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Metabolic Abnormalities in Diabetes and Kidney Disease: Role of Uremic Toxins.
    Koppe L; Fouque D; Soulage CO
    Curr Diab Rep; 2018 Sep; 18(10):97. PubMed ID: 30194541
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Current updates on metabolites and its interlinked pathways as biomarkers for diabetic kidney disease: A systematic review.
    Das S; Devi Rajeswari V; Venkatraman G; Elumalai R; Dhanasekaran S; Ramanathan G
    Transl Res; 2024 Mar; 265():71-87. PubMed ID: 37952771
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The interplay among gut microbiota, hypertension and kidney diseases: The role of short-chain fatty acids.
    Felizardo RJF; Watanabe IKM; Dardi P; Rossoni LV; Câmara NOS
    Pharmacol Res; 2019 Mar; 141():366-377. PubMed ID: 30639376
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Microbiome in Chronic Kidney Disease (CKD): An Omics Perspective.
    Lohia S; Vlahou A; Zoidakis J
    Toxins (Basel); 2022 Feb; 14(3):. PubMed ID: 35324673
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tangshen formula modulates gut Microbiota and reduces gut-derived toxins in diabetic nephropathy rats.
    Zhao T; Zhang H; Yin X; Zhao H; Ma L; Yan M; Peng L; Wang Q; Dong X; Li P
    Biomed Pharmacother; 2020 Sep; 129():110325. PubMed ID: 32535383
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Gut Microbiome in Chronic Kidney Disease.
    Armani RG; Ramezani A; Yasir A; Sharama S; Canziani MEF; Raj DS
    Curr Hypertens Rep; 2017 Apr; 19(4):29. PubMed ID: 28343357
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The gut-kidney axis.
    Evenepoel P; Poesen R; Meijers B
    Pediatr Nephrol; 2017 Nov; 32(11):2005-2014. PubMed ID: 27848096
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evaluation of the impact of gut microbiota on uremic solute accumulation by a CE-TOFMS-based metabolomics approach.
    Mishima E; Fukuda S; Mukawa C; Yuri A; Kanemitsu Y; Matsumoto Y; Akiyama Y; Fukuda NN; Tsukamoto H; Asaji K; Shima H; Kikuchi K; Suzuki C; Suzuki T; Tomioka Y; Soga T; Ito S; Abe T
    Kidney Int; 2017 Sep; 92(3):634-645. PubMed ID: 28396122
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Intestinal microbiota alterations in chronic kidney disease and the influence of dietary components.
    Ondrussek-Sekac M; Navas-Carrillo D; Orenes-Piñero E
    Crit Rev Food Sci Nutr; 2021; 61(9):1490-1502. PubMed ID: 32393049
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The Role of the Gut Microbiome on Chronic Kidney Disease.
    Sampaio-Maia B; Simões-Silva L; Pestana M; Araujo R; Soares-Silva IJ
    Adv Appl Microbiol; 2016; 96():65-94. PubMed ID: 27565581
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dysbiosis-Related Advanced Glycation Endproducts and Trimethylamine N-Oxide in Chronic Kidney Disease.
    Taguchi K; Fukami K; Elias BC; Brooks CR
    Toxins (Basel); 2021 May; 13(5):. PubMed ID: 34069405
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Gut microbiota microbial metabolites in diabetic nephropathy patients: far to go.
    Yu JX; Chen X; Zang SG; Chen X; Wu YY; Wu LP; Xuan SH
    Front Cell Infect Microbiol; 2024; 14():1359432. PubMed ID: 38779567
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.